clinical trial · NCT06916793
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Androgenetic AlopeciaCKD-843 dose#1CKD-843 dose#2Placebo of CKD-843 doseDutasteride CapsulesPlacebo of Dutasteride Capsule
brief summary
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
started
Apr 30, 2025
primary completion
Dec 19, 2026
completion
Sep 17, 2027
last updated
Apr 8, 2025
detailed description
The participants were randomly assigned to one of the following groups: CKD-843 dose #1, CKD-843 dose #2, placebo, or Dutasteride group. They received the assigned medication, placebo for blinding, or the reference drug over a 12-month period.
official title
A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol